Cognitive impairment in first-episode drug-naïve patients with schizophrenia: Relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor

Xiao, Wenhuan; Ye, Fei; Liu, Chunlai; Tang, Xiaowei; Li, Jin; Dong, Hui; Sha, Wei; Zhang, Xiaobin

doi:10.1016/j.pnpbp.2017.03.013

Cited by 32 publications

(22 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only cross-sectional studies are included in this meta-analysis as very few studies investigated the relationship between change scores of BDNF and cognition over time (Vinogradov et al ., 2009). Also, the effect of neurotrophic factors other than BDNF is a neglected area in schizophrenia, other than a very few studies investigating the relationship between glial cell line-derived neurotrophic factor and cognition (Niitsu et al ., 2014; Xiao et al ., 2017).…”

Section: Discussionmentioning

confidence: 99%

Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis

Bora

2019

Psychol. Med.

105

View full text Add to dashboard Cite

BackgroundSchizophrenia is associated with significant cognitive impairment. However, the pathophysiological mechanisms underlying cognitive dysfunction in schizophrenia remain unclear. Brain-derived neurotrophic factor (BDNF) and C-reactive protein (CRP) are among the most commonly investigated peripheral markers of cognition in schizophrenia.MethodsA systematic review in PubMed and Scopus databases was performed until 31 January 2019 to assess the relationship between cognitive impairment, CRP and BDNF levels in schizophrenia. A random-effects meta-analysis was conducted.ResultsCurrent meta-analysis included 21 studies including 2449 patients with schizophrenia-spectrum disorders. Overall, both BDNF [r = 0.12, confidence interval (CI) 0.04–0.19] and CRP (r = −0.13, CI 0.08–0.18) levels were very modestly but significantly related to cognitive functioning in schizophrenia (r = 0.12, CI 0.04–0.19). In meta-analyses of cognitive domains, BDNF levels were significantly associated with verbal memory (r = 0.16, CI 0.09–0.23), working memory (r = 0.14, CI 0.06–0.22), processing speed (r = 0.18, CI 0.10–0.26) and verbal fluency (r = 0.09, CI 0–0.18) performances. Elevated CRP levels were related to all cognitive domains (r = −0.09 to −0.13) except for fluency. Subgroup analyses suggested that the relationship between cognitive and BDNF levels were more pronounced in chronic samples.ConclusionsCurrent findings suggest that cognitive impairment in schizophrenia is significantly related to elevated CRP and reduced BDNF levels in schizophrenia, particularly in chronic samples. However, small effect sizes of these correlations suggest that inflammation and decreased BDNF levels do not play a major role in cognitive dysfunction in most patients with schizophrenia. Further studies are needed to investigate the potential intermediating and confounding factors which can influence the level of relationship between inflammation, neurotrophic factors and cognition in schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis

Bora

2019

Psychol. Med.

105

View full text Add to dashboard Cite

show abstract

“…However, one study has shown that higher GDNF levels result in more severe attention deficit in schizophrenia outpatients [15]. But we found that lower serum levels of GDNF were associated with more severe cognitive impairment in attention distribution and verbal fluency in first-episode schizophrenics in our previous study [8]. The differences of sample sources, subject characteristics, and study paradigms in these studies may be one of the reasons for the inconsistent findings.…”

Section: Discussionmentioning

confidence: 54%

“…Many evidences suggest that BDNF is involved in the pathophysiological process of schizophrenia [5]. Previous studies have shown that peripheral BDNF in patients with chronic or first-episode schizophrenia are decreased, while BDNF mRNA was reduced in the postmortem brain of patients [6–8]. However, other reports have shown inconsistent results [9].…”

Section: Introductionmentioning

confidence: 99%

“…Schizophrenics have a wide range of cognitive deficits, such as learning, memory, executive function and attention. Animal models and clinical trials have also shown that BDNF levels are positively correlated with cognitive impairment [8, 11–13]. Glial cell line- derived neurotrophic factor (GDNF) is one of the most potent trophic factors for dopaminergic neurons of the mammalian CNS.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, GDNF may be potentially relevant to the dopaminergic and neurodevelopmental hypothesis of schizophrenia. Four studies published so far on GDNF serum levels in schizophrenia [8, 15–17] have shown inconsistent results, two of which suggested that serum GDNF levels were associated with cognitive function [8, 15]. Considering these conflicting results, the relationship between NFs and schizophrenia needs to be studied further.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background To measure the serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in deficit schizophrenia (DS), in order to examine the association between these two neurotrophic factors (NFs) and cognitive performance. Methods A total of 109 male patients [51 DS and 58 non-deficit schizophrenia (NDS)] with schizophrenia and 40 sex and age matched healthy controls (HC) participated in this study. Processing speed, attention, executive function, and working memory of all subjects were assessed by means of a battery of classical neuropsychological tests. Serum BDNF and GDNF levels were measured simultaneously using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results There were significant differences in the overall cognitive test scores between three groups (all p < 0.001). Serum BDNF levels were significantly lower in patients (DS and NDS) than in HC ( p < 0.001). Furthermore, BDNF levels were lower in the DS compared to the NDS group, although not significantly. However, there was no difference in the GDNF levels between patients (DS and NDS) and HC. GDNF levels were positively correlated with scores of Stroop words only ( r = 0.311, p = 0.033), Stroop colors only ( r = 0.356, p = 0.014) and Stroop interference ( r = 0.348, p = 0.016) in DS group . Conclusion Serum BDNF may be an unsuitable biomarker for DS, despite a significant decrease in schizophrenia patients. The different neurocognitive performance between the DS and NDS patients indicates that DS may be a separate clinical entity of schizophrenia. Finally, higher serum GDNF levels are associated with better cognitive performance in DS patients, indicating a possible neuroprotective function in DS.

show abstract

Associations between brain‐derived neurotrophic factor and cognitive impairment in panic disorder

Wang

Liu

Luo³

et al. 2020

Brain and Behavior

View full text Add to dashboard Cite

show abstract

Cognitive impairment in first-episode drug-naïve patients with schizophrenia: Relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor

Cited by 32 publications

References 51 publications

Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis

Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

Associations between brain‐derived neurotrophic factor and cognitive impairment in panic disorder

Contact Info

Product

Resources

About